Abstract:Ewing's sarcoma (ES) represents a rare yet exceedingly aggressive neoplasm that poses a significant health risk to the pediatric and adolescent population. The clinical outcomes for individuals with relapsed or refractory ES are notably adverse, primarily attributed to the constrained therapeutic alternatives available. Despite significant advancements in the field, molecular pathology-driven therapeutic strategies have yet to achieve a definitive reduction in the mortality rates associated with ES. Consequently, there exists an imperative need to discover innovative therapeutic targets to effectively combat ES. To reveal the mechanism of the SETD8 (also known as lysine methyltransferase 5A) inhibitor UNC0379, cell death manners were analyzed with different inhibitors. The contributions of SETD8 to the processes of apoptosis and ferroptosis in ES cells were evaluated employing the histone methyltransferase inhibitor UNC0379 in conjunction with RNA interference techniques. The molecular regulatory mechanisms of SETD8 in ES were examined through the application of RNA sequencing (RNA-seq) and mass spectrometry-based proteomic analysis. Moreover, nude mouse xenograft models were established to explore the role of SETD8 in ES in vivo. SETD8, a sole nucleosome-specific methyltransferase that catalyzes mono-methylation of histone H4 at lysine 20 (H4K20me1), was found to be upregulated in ES, and its overexpression was associated with dismal outcomes of patients. SETD8 knockdown dramatically induced the apoptosis and ferroptosis of ES cells in vitro and suppressed tumorigenesis in vivo. Mechanistic investigations revealed that SETD8 facilitated the nuclear translocation of YBX1 through post-transcriptional regulatory mechanisms, which subsequently culminated in the transcriptional upregulation of RAC3. In summary, SETD8 inhibits the apoptosis and ferroptosis of ES cells through the YBX1/RAC3 axis, which provides new insights into the mechanism of tumorigenesis of ES. SETD8 may be a potential target for clinical intervention in ES patients.

SETD8 induces stemness and epithelial–mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression

SETD8 Potentiates Constitutive ERK1/2 Activation Via Epigenetically Silencing DUSP10 Expression in Pancreatic Cancer.

MiR-502/SET8 regulatory circuit in pathobiology of breast cancer.

SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis

SETD8 is a Prognostic Biomarker That Contributes to Stem-Like Cell Properties in Non-Small Cell Lung Cancer.

Single-cell Transcriptome Reveals the Heterogeneity of Malignant Ductal Cells and the Prognostic Value of REG4 and SPINK1 in Primary Pancreatic Ductal Adenocarcinoma

Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.

Methyltransferase SETD2 Inhibits Tumor Growth and Metastasis via STAT1‐IL‐8 signaling mediated EMT in lung adenocarcinoma

Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis

SETD8 promotes stemness characteristics and is a potential prognostic biomarker of gastric adenocarcinoma.

SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways

Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1–IL‐8 signaling‐mediated epithelial–mesenchymal transition in lung adenocarcinoma

SETDB1 confers colorectal cancer metastasis by regulation of WNT/-catenin signaling

Cooperation between IRTKS and deubiquitinase OTUD4 enhances the SETDB1-mediated H3K9 trimethylation that promotes tumor metastasis via suppressing E-cadherin expression

DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer

Monomethyltransferase SETD8 Regulates Breast Cancer Metabolism Via Stabilizing Hypoxia-Inducible Factor 1Α.

SETD7 Promotes Cell Proliferation and Migration Via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma

Microrna-148a-3p Suppresses Epithelial-To-Mesenchymal Transition And Stemness Properties Via Wnt1-Mediated Wnt/Beta-Catenin Pathway In Pancreatic Cancer

SETD8 inhibition targets cancer cells with increased rates of ribosome biogenesis

RER1 Enhances Carcinogenesis and Stemness of Pancreatic Cancer under Hypoxic Environment